The World Bank Annual Report 2011

Bank, World

doi:10.1596/978-0-8213-8828-0

Cited by 217 publications

(99 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Therefore, further research in this area is needed (Blanco et al, 2013;Hernandez & Torero, 2014;Schreiner, 2002;Serrano-Cinca et al, 2016), and an incorrect assessment of client credibility can affect the stability of the MFI. Furthermore, international organizations have emphasized that credit risk analysis should also address systemic factors (specific to the socio-economic context), in addition to idiosyncratic ones, due to the vulnerability of microfinance portfolios to macroeconomic changes (EU, 2015;IMF, 2015;US Department of Treasury, 2013;USAID, 2011;World Bank, 2014).…”

Section: Literature Reviewmentioning

confidence: 99%

Analysis of default risk in microfinance institutions under the Basel III framework

2021

View full text Add to dashboard Cite

International organizations such as OECD, WBG, IMF, UN and EU, as well as research studies, have highlighted the increasing contribution being made by microcredit finance institutions (MFIs) to financial inclusion, sustainable economic development and the fight against poverty. However, access to MFI credit is still far from the desired level for small and micro-enterprises, especially in developing countries. The countries of Latin America and the Caribbean, where approximately half of the small formal companies do not have access to credit, have the world's highest financial gap ratio compared to potential demand (87%). In this context, effective instruments are needed to assess default risk, through credit ratings. Based on the Basel III regulations, an empirical study was conducted of two microcredit portfolios corresponding to two MFIs in two Latin American countries (Bolivia and Colombia) during the period 2012-2015, to identify the explanatory variables of the probability of default on loans granted by MFIs, using a logistic regression model and a neural network. The results obtained show that the main variables in this respect are the amount of the loan, the number of payments in arrears, the guarantees provided, the assessment of the credit analyst, male gender of the borrower and the level and trend of the general stock exchange index. The conclusions presented advance previous research findings and may be useful for MFI managers, regulatory institutions, financial analysts, scholars, policy-makers and applicants for microcredits to undertake a business project, especially in times of emerging crisis, such as that caused by the Covid-19 pandemic.

show abstract

Section: Literature Reviewmentioning

confidence: 99%

Analysis of default risk in microfinance institutions under the Basel III framework

2021

View full text Add to dashboard Cite

show abstract

“…the world report on disability by World Health Organization and World Bank (2011) show higher percentages than the mentioned national ones. …”

Section: Factual Information Concerning Disability In the Gccmentioning

confidence: 73%

Disability Protection in Work-Family Balance Policies in the Gulf Cooperation Council

Aref¹,

Attia

2017

pijss

View full text Add to dashboard Cite

show abstract

“…Excessive research in the development of PD-1/PD-L1 inhibitors may cause wastage of clinical materials and scientific research funds after prolonged research without results. Furthermore, the drug market is highly competitive given the global economic downturn in recent years ( The World Bank, 2022 ). However, the bibliometric analysis of the health economics of Camrelizumab has already revealed that even with the impact of the global great economic downturn, for countries that are still developing in this field, the second option—that is, applying money, manpower, and time for the development of new drugs—is a possible but necessary path.…”

Section: Discussionmentioning

confidence: 99%

Global trends in the health economics field of PD-1/PD-L1 inhibitors: A bibliometric and visualized study

Lai

Zhang

et al. 2023

Front. Pharmacol.

View full text Add to dashboard Cite

Inhibitors of programmed cell death protein 1 and its associated ligand (PD-L1) are widely used in cancer treatment. However, medical costs and benefits of PD-1/PD-L1 inhibitors need attention owing to differences in response rates among individuals. This study explored global trends in the health economics field of PD-1/PD-L1 inhibitors to enhance their worldwide development. Bibliometric analysis of all documents currently indexed in Web of Science Core Collection from inception to 2022 was performed. Publication year, authors, countries, institutes, and journals were analyzed by Bibliometrix package (version 3.2.1) in R (version 4.1.3). CiteSpace (version 6.1.R6) and VOSviewer (version 1.6.18) were used to analyze burst words, co-authorship of institutes, co-cited journals, and co-cited references, while figures were mainly drawn by Ggplot2 package (version 3.3.5) in R (version 4.1.3) and SCImago Graphica Beta (version 1.0.23). A total of 2020 documents related to the health economics of PD-1/PD-L1 inhibitors were identified, and 1,204 documents met the selection criteria for inclusion in the study. A rapid increase in the number of publications since 2019 was observed, but this increase stopped in 2022, revealing research saturation in the field. Value in Health (166 publications, 13.79% of total documents) had the most publications, while New England Journal of Medicine (2,890 co-citations) was the most co-cited journal. The United States was the leading contributor in this field with 506 publications and the top two productive institutes globally. The main hot topics included the cost-effectiveness of treatment with PD-1 and/or PD-L1 inhibitors, and the comparison between the cost-effectiveness of PD-/PD-L1 inhibitors and other drugs. There were substantial differences between developed and developing countries in the health economics field of PD-1 and/or PD-L1 inhibitors. The cost-effectiveness analysis of combined treatment with PD-1/PD-L1 inhibitors and other drugs warrants further attention. Findings from this study may provide governments and pharmaceutical companies with a strong reference for future research.

show abstract

The World Bank Annual Report 2011

Cited by 217 publications

References 0 publications

Analysis of default risk in microfinance institutions under the Basel III framework

Analysis of default risk in microfinance institutions under the Basel III framework

Disability Protection in Work-Family Balance Policies in the Gulf Cooperation Council

Global trends in the health economics field of PD-1/PD-L1 inhibitors: A bibliometric and visualized study

Contact Info

Product

Resources

About